The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure–Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial

Abstract

It was possible to retrospectively estimate frailty in a trial population, and this FI identified those at higher risk of poor outcomes. Participants with frailty had some attenuation of benefit from intensive glucose-lowering and BP-lowering treatments.